Connor, Clark & Lunn Investment Management (CC&L)
TSHA icon

Connor, Clark & Lunn Investment Management (CC&L)’s Taysha Gene Therapies TSHA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-112,413
Closed -$323K – 1700
2024
Q1 		$323K Buy
112,413
+77,013
+218% +$160K ﹤0.01% 1243
2023
Q4 		$62.7K Buy
+35,400
New +$70.6K ﹤0.01% 1333

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TSHA Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Taysha Gene Therapies (TSHA) in Q2 2024, closing a stake of 112,413 shares — an estimated $323K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TSHA in Q4 2023 and held it in 2 quarters. The position peaked at $323K in Q1 2024. 107 funds tracked by Wall St. Rank hold TSHA as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Taysha Gene Therapies position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 112,413 Taysha Gene Therapies shares in Q2 2024, an estimated $323K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Taysha Gene Therapies in Q4 2023 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Taysha Gene Therapies position peaked at $323K in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.